Evidence map›Paper›PMID 24616657›Full record

ArticleFrontiers in neuroscience2014

Orexin-1 and orexin-2 receptor antagonists reduce ethanol self-administration in high-drinking rodent models.

Rachel I Anderson, Howard C Becker, Benjamin L Adams, Cynthia D Jesudason, Linda M Rorick-Kehn

Open access · goldAbstract read
In one paragraph

Article in Frontiers in neuroscience, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 63 papers.

0numbers the graph read from it
0cells of the map it votes in
63citing papers in PubMed
4.9field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

63 citing papers in PubMed, 96 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Review
  5. Review
  6. Review
  7. Article
  8. Article
  9. Chronic alcohol withdrawal-associated increases in VTAAdvances in drug and alcohol research · 2025
    Article
  10. Review
  11. Mouse parasubthalamicbioRxiv : the preprint server for biology · 2024
    Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Review
  17. Article
  18. Article
  19. Article
  20. Review

3 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 1 country.

Rachel I AndersonMedical University of South Carolina Charleston, SC, USA ; Charleston Alcohol Research Center Charleston, SC, USA.
Howard C BeckerMedical University of South Carolina Charleston, SC, USA ; Charleston Alcohol Research Center Charleston, SC, USA ; Ralph H. Johnson VA Medical Center USA.
Benjamin L AdamsLilly Research Laboratories, Eli Lilly and Company Indianapolis, IN, USA.
Cynthia D JesudasonLilly Research Laboratories, Eli Lilly and Company Indianapolis, IN, USA.
Linda M Rorick-KehnLilly Research Laboratories, Eli Lilly and Company Indianapolis, IN, USA.
Eli Lilly (United States) · USMedical University of South Carolina · USRalph H. Johnson VA Medical Center · US

Funding

TREATING ETHANOL WITHDRAWAL WITH LORAZEPAM/NALTREXONEP50AA010761 · NIAAA · MEDICAL UNIVERSITY OF SOUTH CAROLINA · PI Lisa M McTeague · 1996 to 2026
$46.8M
Ethanol Dependence &Stress Effects on Ethanol DrinkingU01AA014095 · NIAAA · MEDICAL UNIVERSITY OF SOUTH CAROLINA · PI HOWARD C. BECKER · 2003 to 2026
$9.0M
TRAINING IN ALCOHOL TREATMENT RESEARCHT32AA007474 · NIAAA · MEDICAL UNIVERSITY OF SOUTH CAROLINA · PI John J. Woodward · 1987 to 2026
$8.5M
Mouse Chronic Intermittent Ethanol (CIE) CoreU01AA020929 · NIAAA · MEDICAL UNIVERSITY OF SOUTH CAROLINA · PI LOPEZ, MARCELO F. · 2012 to 2015
$1.5M
NIAAA NIH HHS P50 AA010761NIAAA NIH HHS T32 AA007474NIAAA NIH HHS U01 AA014095NIAAA NIH HHS U01 AA020929
6 · The paper itself

Abstract

To examine the role of orexin-1 and orexin-2 receptor activity on ethanol self-administration, compounds that differentially target orexin (OX) receptor subtypes were assessed in various self-administration paradigms using high-drinking rodent models. Effects of the OX1 antagonist SB334867, the OX2 antagonist LSN2424100, and the mixed OX1/2 antagonist almorexant (ACT-078573) on home cage ethanol consumption were tested in ethanol-preferring (P) rats using a 2-bottle choice procedure. In separate experiments, effects of SB334867, LSN2424100, and almorexant on operant ethanol self-administration were assessed in P rats maintained on a progressive ratio operant schedule of reinforcement. In a third series of experiments, SB334867, LSN2424100, and almorexant were administered to ethanol-preferring C57BL/6J mice to examine effects of OX receptor blockade on ethanol intake in a binge-like drinking (drinking-in-the-dark) model. In P rats with chronic home cage free-choice ethanol access, SB334867 and almorexant significantly reduced ethanol intake, but almorexant also reduced water intake, suggesting non-specific effects on consummatory behavior. In the progressive ratio operant experiments, LSN2424100 and almorexant reduced breakpoints and ethanol consumption in P rats, whereas the almorexant inactive enantiomer and SB334867 did not significantly affect the motivation to consume ethanol. As expected, vehicle-injected mice exhibited binge-like drinking patterns in the drinking-in-the-dark model. All three OX antagonists reduced both ethanol intake and resulting blood ethanol concentrations relative to vehicle-injected controls, but SB334867 and LSN2424100 also reduced sucrose consumption in a different cohort of mice, suggesting non-specific effects. Collectively, these results contribute to a growing body of evidence indicating that OX1 and OX2 receptor activity influences ethanol self-administration, although the effects may not be selective for ethanol consumption.

Indexed as

C57BL/6J mouseethanol consumptionhypocretins/orexinsoperant progressive ratioP rat

Identifiers

PMID24616657
PMCPMC3933945
OpenAlexW2006176585

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.